Results 101 to 110 of about 143,948 (293)
Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target. [PDF]
, 2018 Prostate cancer (PCa) is a leading cause of mortality and morbidity globally. While genomic alterations have been identified in PCa, in contrast to some other cancers, use of such information to personalize treatment is still in its infancy.
Dorff, Tanya +6 more
core +3 more sources
Patient Related Outcome Measures, 2011 Bob Djavan, Seyed Saeid Dianat, Amir KazzaziNew York University, Department of Urology, New York, USABackground: Benign prostatic hyperplasia, the fourth most commonly diagnosed medical condition in the elderly, is a major underlying cause of lower ...
Djavan B, Dianat SS, Kazzazi A
doaj
Role of prostatic artery embolization in management of symptomatic benign prostatic hyperplasia
The Egyptian Journal of Radiology and Nuclear Medicine, 2016 Objectives: To assess the feasibility and efficacy of prostatic artery embolization in relieving symptoms of benign prostatic hyperplasia. Materials and methods: In a prospective study 28 patients with symptomatic benign prostatic hyperplasia were ...
Mohamed Shaker +3 more
doaj +1 more source
A brief review of the literature on the malignant ureteral obstruction [PDF]
, 2018 Malignant ureteral obstruction (MUO) caused by a primarily urological tumor or secondary to a late-stage malignancy can be difficult for the urologist to manage. Due to a lack of clinical data on the management of MUO, every case is particular and should
Brînză, Adrian +7 more
core +1 more source
Short-term pretreatment with a dual 5α-reductase inhibitor before bipolar transurethral resection of the prostate (b-turp): evaluation of prostate vascularity and decreased surgical blood loss in large prostates [PDF]
, 2015 Objective: To investigate if short-term treatment with dutasteride (8 weeks) before bipolar transurethral resection of the prostate (B-TURP) can reduce intraoperative bleeding, as dutasteride a dual 5α-reductase inhibitor (5-ARI) blocks the conversion of
Amory +28 more
core +1 more source
UroPrecision, EarlyView.Abstract Prostate cancer (PCa) is a multifaceted disease that envelops 1.41 million new cases globally. It is the second most common cancer reported in men. Its heterogeneity and indolent growth, coupled with incompetent early screening methods such as serum prostate‐specific antigen level estimations and digital rectal examinations, contribute to its ...
Anveshika Manoj +2 more
wiley +1 more source
PSA – biomarker, mis on muutnud eesnäärmehaiguste kliinilist käsitlust [PDF]
, 2009 Prostataspetsiifi line antigeen on enim kasutatav eesnäärmehaiguste marker kliinilises meditsiinis, mille tähtsus prostata biomarkerina avastati 1979. aastal. Oluline on teada, et PSA on eesnäärme-, mitte kasvajaspetsiifi line marker.
Ausmees, Kristo, Žarkovski, Mihhail
core +2 more sources
Iraqi Journal of Pharmaceutical SciencesPterostilbene is a potent anti-inflammatory and antioxidant used to treat benign prostatic hyperplasia, which is brought on by the induction of testosterone propionate.
Mohammed Ridha Jawad, Ghaith Ali Jasim
doaj +1 more source
BJU International, 2018 To comprehensively evaluate the efficacy and safety of the hexanic extract of Serenoa repens (HESr, Permixon®; Pierre Fabre Médicament, Castres, France), at a dose of 320 mg daily, as monotherapy for the treatment of lower urinary tract symptoms ...
R. Vela-Navarrete +16 more
semanticscholar +1 more source
Chronic kidney disease and urological disorders: systematic use of uroflowmetry in nephropathic patients [PDF]
, 2018 Background. Chronic kidney disease (CKD) is a highly prevalent condition. Urologic disorders are known causes of CKD, but often remain undiagnosed and underestimated also for their insidious onset and slow progression.
Ciccariello, Mauro +12 more
core